Sustained Release Excipients Market Expansion to $2.1 Billion by 2029: Key Drivers and Trends

Uncover key drivers, emerging technologies, and competitive movements shaping the sustained release excipients market from 2025–2034 with trusted insights from The Business Research Company

What Is The Base Market Size For The Sustained Release Excipients Market Today And What Will It Reach By 2029?

The sustained release excipients market size has experienced robust growth over recent years. It is anticipated to expand from $1.4 billion in 2024 to $1.51 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.1%. This historical growth can be attributed to factors such as a rise in demand for controlled drug release, the prevalence of chronic diseases, improved patient compliance and convenience, innovations within the pharmaceutical industry, and regulatory backing for extended-release formulations.

The sustained release excipients market is projected to experience robust expansion over the coming years. It is set to reach $2.1 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is primarily driven by an increasing elderly population, a heightened focus on personalized medicine, persistent challenges in patient adherence, the emergence of more complex drug formulations, continuous advancements in disease management, and the global expansion of healthcare. Prominent trends expected over this period include patient-centric approaches to drug delivery, strategic collaborations for formulation development, stringent regulatory compliance and safety measures, the worldwide proliferation of drug formulation technologies, and the increasing influence of biopharmaceuticals.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp

What Factors Are Boosting The Sustained Release Excipients Market?

The sustained-release excipients market is anticipated to experience growth due to the escalating prevalence of chronic and acute diseases. These illnesses are categorized distinctly based on their duration and progression. Chronic diseases are long-term medical conditions that typically last for three months or more, whereas acute diseases are characterized by a swift onset of symptoms that are usually severe but short-lived, often resolving within hours, days, or weeks. Sustained-release excipients are extensively employed in formulating pharmaceutical products for both chronic and acute conditions. Their benefits, including improved patient adherence, maintenance of consistent drug levels, reduction of side effects, and better disease management, contribute to increased sales of sustained-release excipients. For instance, in September 2022, the World Health Organization (WHO), a Switzerland-based specialized health agency, reported that cardiovascular diseases accounted for the largest share of non-communicable disease (NCD) deaths, totaling 17.9 million people annually. This was followed by cancer (9.3 million), chronic respiratory illnesses (4.1 million), and diabetes (2.0 million, which includes fatalities from renal disease caused by diabetes). Furthermore, an August 2022 report from the American College of Cardiology, a US-based non-profit medical association, projected an increase in all four major cardiovascular risk factors in the United States from 2025 to 2060. Diabetes is expected to show the most significant percentage rise, with a 39.3% increase to 55 million individuals. Hypertension is projected to increase by 25.1% to 162 million, dyslipidemia by 27.6% to 126 million, and obesity by 18.3% to 126 million. Additionally, substantial increases in cardiovascular disease rates are foreseen for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) also seeing significant rises. Consequently, the rising incidence of chronic and acute diseases acts as a primary driver for the growth of the sustained-release excipients market.

How Is The Sustained Release Excipients Market Categorized By Application, Type, And Region?

The sustained release excipients market covered in this report is segmented –

1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan

2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration

3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation

Subsegments:

1) By Gelatin: Type A Gelatin, Type B Gelatin

2) By Polymers: Natural Polymers, Synthetic Polymers

3) By Minerals: Calcium Compounds, Magnesium Compounds, Other Mineral Excipients

4) By Sugars: Sucrose, Lactose, Glucose, Other Sugars

5) By Alcohol: Ethanol, Isopropyl Alcohol, Other Alcohols

6) By Chitosan: Low Molecular Weight Chitosan, High Molecular Weight Chitosan

How Are Technological Trends Affecting The Sustained Release Excipients Market Growth?

Product innovation stands out as a significant trend gaining momentum within the sustained release excipients market. Major companies operating in the sustained release excipients market are actively developing novel products to enhance their position. For example, in September 2022, Nutriventia Limited, an India-based pharmaceutical company, introduced Prolanza, a sustained-release ashwagandha ingredient (Withania somnifera). This advanced Ashwagandha root-only extract provides continuous support for stress reduction. Prolanza’s distinctive release mechanism allows its therapeutic effects to last over an extended period with just one daily dose. When compared to the control component, Prolanza ashwagandha exhibited superior relative absorption, improved bioavailability, and a prolonged elimination half-life, indicating a sustained-release profile. As ashwagandha is primarily used for its capacity to adapt and mitigate stress responses, Prolanza’s therapeutic effects will endure longer and have a greater overall positive influence on health. It is made from natural herbs and has been clinically verified for its effectiveness.

Who Are The Global Leaders Steering The Sustained Release Excipients Market Forward?

Major companies operating in the sustained release excipients market include BASF SE, Ashland Global Holdings Inc., Colorcon Inc., Croda International Plc, Dow Chemical Company, DuPont de Nemours Inc., Roquette Frères, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, JRS Pharma GmbH & Co. KG, Shin-Etsu Chemical Co.Ltd., Gattefossé SAS, Eastman Chemical Company, Cellulose Solutions Private Limited, Avantor Inc., SPI Pharma Inc., Asahi Kasei Corporation, Chemische Fabrik Budenheim KG, Associated British Foods plc, Ransom Naturals Ltd, Balchem Corporation, IMCD Group, Lonza Group AG

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Sustained Release Excipients Market?

North America was the largest region in the global sustained release excipients market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10822&type=smp

Browse Through More Reports Similar to the Global Sustained Release Excipients Market 2025, By The Business Research Company

Pharmaceutical Excipient Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Telemedicine Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/telemedicine-services-global-market-report

Animal Medicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795